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Fig. 1. Change in the eczema area and severity index (EASI) score 
before and after azathioprine treatment (mean treatment 
duration, 22.20±19.84 weeks). There was a 42% reduction in 
the EASI score from the baseline (p＜0.017). *Statistically 
significant difference compared with the baseline.
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Dear Editor:
Atopic dermatitis (AD) is a chronic, distressing disease of-
ten requiring systemic treatment for disease control1. Drug 
candidates for AD, however, are limited; the long-term 
use of systemic steroid raises concerns for metabolic ad-
verse effects, and cyclosporine has potential nephrotox-
icity and is contraindicated in uncontrolled hypertensive 
patients. Azathioprine, an imidazole derivative of 6-mer-
captopurine, is one of the alternative choices in the treat-
ment of recalcitrant AD. Yet, its efficacy in AD patients 
has not been thoroughly investigated in Asian population.
From a computerized institutional database, we identified 
AD patients who underwent treatment with azathioprine 
from December 2009 to January 2011. A total of 20 pa-
tients were included (16 men, 4 women; mean age, 
28.65±9.51 years; range, 13∼43 years). Azathioprine 
was started at a dose of 100 mg/day. All patients were al-
lowed to take antihistamine and topical steroids for symp-
tomatic control and the management of localized lesions. 
The mean duration of azathioprine treatment was 22.20± 
19.85 weeks.
Overall, compared with baseline, improvements were ob-
served in the eczema area and severity index (EASI) score 
from 26.12±3.20 to 15.15±3.05 (p＜0.017) (Fig. 1). On 
the visual analogue scale, the degree of pruritus decreased 
from 7.35±1.66 to 4.10±2.89 (p＜0.001) along with a 
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Fig. 2. Changes in pruritus and loss of sleep (LOS) before and 
after azathioprine treatment (mean treatment duration, 
22.20±19.84 weeks). On the visual analogue scale, the degree 
of pruritus decreased from 7.35±1.66 to 4.10±2.89 (p＜0.001), 
and LOS decreased from 6.55±1.88 to 3.10±2.86 (p＜0.001). 
*Statistically significant difference compared with the baseline.
decrease in loss of sleep from 6.55±1.88 to 3.10±2.86 (p
＜0.001) (Fig. 2).
When azathioprine was insufficient in controlling flare-ups, 
the patients were prescribed with systemic steroid as a res-
cue drug. In our review, 40% (8 of 20) of the patients 
needed a rescue drug during the course of azathioprine 
treatment. After the discontinuation of azathioprine, 45% 
(9 of 20) of the patients were able to remain on a minimal 
disease status with only antihistamine, topical im-
munomodulators, or topical steroids. 
In this study, we observed that after an average of 
22.20±19.84 weeks of azathioprine treatment, 55% (11 
of 20) of the patients reported “excellent” outcome ac-
cording to Investigator’s Global Assessment of clinical 
response. Our result was comparable to the 60% re-
mission rate achieved in a study group of 37 patients treat-
ed with azathioprine during an 18-year period2.
The decrease of EASI score in our study was higher than in 
previously reported placebo-controlled studies on azathio-
prine (26%3 or 37%4 reduction in severity). However, the 
improvement rate should take into consideration those 
who took rescue drugs. 
For the adverse effects, there were no hypersensitivity 
reactions. Also, regular monitoring of complete blood 
count and routine chemistry did not show noticeable 
results. Although we have treated patients tolerant to 100 
mg/day azathioprine for an average period of 88 weeks, 
this study has major limitations as there is no control 
group. The absence of a control group can both over- and 
underestimate the judgment on the efficacy of azathi-
oprine. Nevertheless, decrease in the EASI score and im-
provement in subjective symptoms should provide some 
credentials for the clinical efficacy of azathioprine in AD 
and raise a suggestion that it can be an appropriate candi-
date for adult Asian AD patients who cannot use or are 
not responsive to cyclosporine.
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